PharmAla net loss narrows to CAD 499,759 in Q3 FY26; revenue more than doubled to CAD 513,000

• PharmAla Biotech reported revenue of CAD 1 million+ for the nine months ended May 31, 2026, more than doubled year over year.
• Net loss narrowed to CAD 499,759 for the three months ended May 31, 2026, down 4.67% from a year earlier.
• Nine-month net loss improved to CAD 1.25 million, down 31.26% year over year, primarily due to higher revenue.
• Cash used in operating activities eased to CAD 673,588 for the nine months, down 10.04% from the prior-year period.
• Management highlighted strong quarterly sales, recent licensing agreements, and a Jupiter Neuroscience transaction executed in Q4 as a subsequent event.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmala Biotech Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300730PRIMZONECNPR____9800798) on July 30, 2026, and is solely responsible for the information contained therein.